KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $164.1 million.

  • Neogenomics' Cash & Equivalents fell 5466.28% to $164.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.1 million, marking a year-over-year decrease of 5466.28%. This contributed to the annual value of $367.0 million for FY2024, which is 716.05% up from last year.
  • Latest data reveals that Neogenomics reported Cash & Equivalents of $164.1 million as of Q3 2025, which was down 5466.28% from $154.7 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Cash & Equivalents peaked at $612.0 million during Q1 2021, and registered a low of $154.7 million during Q2 2025.
  • Over the past 5 years, Neogenomics' median Cash & Equivalents value was $316.8 million (recorded in 2021), while the average stood at $318.5 million.
  • Per our database at Business Quant, Neogenomics' Cash & Equivalents skyrocketed by 60949.75% in 2021 and then tumbled by 5642.65% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Cash & Equivalents stood at $316.8 million in 2021, then decreased by 16.93% to $263.2 million in 2022, then soared by 30.13% to $342.5 million in 2023, then grew by 7.16% to $367.0 million in 2024, then crashed by 55.28% to $164.1 million in 2025.
  • Its last three reported values are $164.1 million in Q3 2025, $154.7 million for Q2 2025, and $346.2 million during Q1 2025.